Loading...
01/11 03:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
Revenue $7.6 million for Q3 2025, compared to negative $7.7 million in Q3 2024. The year-over-year increase was due to the timing of revenue recognized under the collaboration agreement with GSK.
Research and Development Expenses $45.9 million in Q3 2025, compared to $41.2 million in Q3 2024. The increase was primarily driven by the advancement of the INHBE program, RNA editing programs, and compensation-related expenses, including share-based compensation.
General and Administrative Expenses $18.1 million in Q3 2025, compared to $15 million in Q3 2024. The increase was primarily related to share-based compensation and other external expenses.
Net Loss $53.9 million for Q3 2025, compared to $61.8 million in Q3 2024. The decrease in net loss was due to increased revenue and controlled expenses.
Cash and Cash Equivalents $196.2 million as of the end of Q3 2025, compared to $302.1 million as of December 31, 2024. The decrease was due to operational expenses, partially offset by $72.1 million in ATM proceeds and committed GSK milestones post-quarter-end.
WVE-007: Demonstrated significant and durable activin E reductions in clinical trials, showing potential for meaningful weight loss and prevention of rebound weight gain. Positioned as a maintenance therapy for obesity with once or twice yearly dosing. Clinical trial data from over 100 participants expected in H1 2026.
WVE-006: Achieved key treatment goals for AATD, including restoring physiological AAT production. Demonstrated durable effects and potential for monthly or less frequent dosing. Data from ongoing trials expected in Q1 2026.
WVE-008: Advanced as a clinical candidate for PNPLA3 I148M liver disease, targeting a population of 9 million in the U.S. and Europe. Clinical planning underway with CTA submission expected in 2026.
WVE-N531: Demonstrated significant improvement in muscle health and time to rise in DMD patients. IND submission for accelerated approval expected in 2026.
WVE-003: Preparing for Phase II/III study in HD, showing potent and durable mutant Huntington reductions. IND application for the study expected in H2 2025.
Obesity market: WVE-007 received significant attention at Obesity Week, highlighting its potential as a non-incretin treatment for obesity with positive engagement from stakeholders.
AATD market: WVE-006 represents a paradigm shift from weekly IV therapies, addressing the root cause of AATD with a convenient subcutaneous dosing.
PNPLA3 I148M liver disease market: WVE-008 targets a large unmet need with no approved medicines addressing this biology, focusing on a population at high risk of liver disease.
Financial performance: Revenue for Q3 2025 was $7.6 million, a significant increase from the prior year. Net loss reduced to $53.9 million from $61.8 million in the prior year. Cash runway extended into Q2 2027 with additional ATM proceeds and GSK milestones.
R&D investment: Increased R&D expenses driven by advancements in INHBE and RNA editing programs.
Pipeline advancement: Rapid progress in RNAi and RNA editing programs, with multiple clinical and preclinical advancements.
Collaborations: Ongoing collaboration with GSK contributing to financial stability and operational progress.
Regulatory Risks: The company acknowledges that forward-looking statements are subject to several risks and uncertainties, which could cause actual results to differ materially. This includes potential regulatory hurdles for their clinical trials and product approvals.
Financial Risks: The company reported a net loss of $53.9 million for Q3 2025, with a significant decrease in cash and cash equivalents from $302.1 million at the end of 2024 to $196.2 million. While additional funding has extended the cash runway into Q2 2027, future milestones and payments under collaborations are not guaranteed.
Clinical Development Risks: The success of the company's pipeline, including WVE-007, WVE-006, and WVE-008, depends on achieving clinical milestones. Delays or failures in clinical trials, such as INLIGHT or RestorAATion-2, could adversely impact the company's strategic objectives.
Market and Competitive Risks: The company faces competitive pressures in the obesity, AATD, and liver disease markets. For example, WVE-007 aims to compete with existing GLP-1 therapies, and WVE-006 seeks to replace weekly IV augmentation therapies. Failure to demonstrate superior efficacy or convenience could limit market adoption.
Operational Risks: The company is advancing multiple programs simultaneously, which could strain resources and operational capacity. Any mismanagement or delays in these programs could impact overall performance.
Economic and Funding Risks: The company is reliant on collaborations, such as with GSK, for funding and milestone payments. Economic uncertainties or changes in partnership dynamics could affect financial stability.
WVE-007 (INHBE GalNAc siRNA): The company plans to deliver data on over 100 participants from clinical trial sites in Europe and the U.S. in the first half of 2026. Early impact of INHBE reduction at 3 months in the 240-milligram cohort will be assessed this quarter. Six-month follow-up data from the 240-milligram cohort and 3-month follow-up data from the 400-milligram cohort will be available in Q1 2026.
WVE-006 (GalNAc RNA editing oligonucleotide for AATD): Dosing is ongoing in the 400-milligram multi-dose cohort, with data expected in Q1 2026. Single and multi-dose data from the 600-milligram cohort will be delivered in 2026.
WVE-008 (GalNAc-conjugated RNA editing program for PNPLA3 I148M liver disease): Clinical planning is underway for the first-in-human study, with a CTA submission on track for 2026.
WVE-N531 (DMD program): The company plans to submit an IND in 2026 for accelerated approval of N531 with a monthly dosing regimen.
WVE-003 (HD program): The company is preparing for a global Phase II/III study using caudate volume as a primary endpoint and plans to submit an IND application in the second half of 2026.
The selected topic was not discussed during the call.
The earnings call summary indicates a mix of positive and cautious elements. While there are promising developments in product pipelines and strategic plans, there are also uncertainties, particularly in the obesity program and AATD study. The Q&A highlighted management's avoidance of specifics, which may raise concerns. No strong catalysts like partnerships or record revenues were mentioned, and the strategic plan lacks immediate financial impact. The absence of market cap data limits assessment of stock sensitivity, but overall sentiment leans towards neutral given the balanced positives and uncertainties.
The earnings call reveals several concerns: a decline in revenue and increased R&D expenses and net loss. Despite the clinical pipeline progress, the market may react negatively to the financial results. The Q&A section highlights uncertainties in dosing strategies and management's reluctance to disclose specific milestone details, which could further erode investor confidence. The positive aspects, such as cash runway and pipeline advancements, are overshadowed by financial underperformance and lack of clarity in strategic execution.
The earnings call summary shows challenges: declining revenue, increased expenses, and a significant net loss, indicating financial strain. The absence of a shareholder return plan is concerning. The Q&A section reveals uncertainties, particularly regarding data disclosure timelines and regulatory approval pathways. Competitive pressures from GLP-1s in obesity treatment and supply chain challenges further exacerbate the negative outlook. While there are some positive aspects, such as cash runway until 2027, the overall sentiment remains negative due to financial strain and uncertainties, likely leading to a stock price decline of -2% to -8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
